Skip to main content

Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’

Sage Therapeutics has to balance two competing interests when it comes to pricing its postpartum depression drug, CEO Jeff Jonas says.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.